PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population

Implications in precision diagnosis

Mariyam Akizhanova, Elzira E. Iskakova, Valdemir Kim, Xiao Wang, Roman Kogay, Aiym Turebayeva, Qinglei Sun, Ting Zheng, Shenghui Wu, Lixia Miao, Yingqiu Xie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68% of patients have cancer with Gleason score ranged 6-8 and 65.77% of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.

Original languageEnglish
Pages (from-to)1223-1228
Number of pages6
JournalJournal of Cancer
Volume8
Issue number7
DOIs
Publication statusPublished - Apr 10 2017

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostate
Prostatic Neoplasms
Health
Population
Biopsy
Neoplasm Grading
Institutional Ethics
Kazakhstan
Hybrid Vigor
Pedigree
Neoplasms
Cohort Studies
History
Databases

Keywords

  • Diagnosis
  • Precision medicine
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Oncology

Cite this

PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population : Implications in precision diagnosis. / Akizhanova, Mariyam; Iskakova, Elzira E.; Kim, Valdemir; Wang, Xiao; Kogay, Roman; Turebayeva, Aiym; Sun, Qinglei; Zheng, Ting; Wu, Shenghui; Miao, Lixia; Xie, Yingqiu.

In: Journal of Cancer, Vol. 8, No. 7, 10.04.2017, p. 1223-1228.

Research output: Contribution to journalArticle

Akizhanova, M, Iskakova, EE, Kim, V, Wang, X, Kogay, R, Turebayeva, A, Sun, Q, Zheng, T, Wu, S, Miao, L & Xie, Y 2017, 'PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: Implications in precision diagnosis', Journal of Cancer, vol. 8, no. 7, pp. 1223-1228. https://doi.org/10.7150/jca.18012
Akizhanova, Mariyam ; Iskakova, Elzira E. ; Kim, Valdemir ; Wang, Xiao ; Kogay, Roman ; Turebayeva, Aiym ; Sun, Qinglei ; Zheng, Ting ; Wu, Shenghui ; Miao, Lixia ; Xie, Yingqiu. / PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population : Implications in precision diagnosis. In: Journal of Cancer. 2017 ; Vol. 8, No. 7. pp. 1223-1228.
@article{a287a211bfc34eddab301e871f0cd198,
title = "PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: Implications in precision diagnosis",
abstract = "Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68{\%} of patients have cancer with Gleason score ranged 6-8 and 65.77{\%} of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.",
keywords = "Diagnosis, Precision medicine, Prostate cancer, PSA",
author = "Mariyam Akizhanova and Iskakova, {Elzira E.} and Valdemir Kim and Xiao Wang and Roman Kogay and Aiym Turebayeva and Qinglei Sun and Ting Zheng and Shenghui Wu and Lixia Miao and Yingqiu Xie",
year = "2017",
month = "4",
day = "10",
doi = "10.7150/jca.18012",
language = "English",
volume = "8",
pages = "1223--1228",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "7",

}

TY - JOUR

T1 - PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population

T2 - Implications in precision diagnosis

AU - Akizhanova, Mariyam

AU - Iskakova, Elzira E.

AU - Kim, Valdemir

AU - Wang, Xiao

AU - Kogay, Roman

AU - Turebayeva, Aiym

AU - Sun, Qinglei

AU - Zheng, Ting

AU - Wu, Shenghui

AU - Miao, Lixia

AU - Xie, Yingqiu

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68% of patients have cancer with Gleason score ranged 6-8 and 65.77% of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.

AB - Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68% of patients have cancer with Gleason score ranged 6-8 and 65.77% of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.

KW - Diagnosis

KW - Precision medicine

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=85017574206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017574206&partnerID=8YFLogxK

U2 - 10.7150/jca.18012

DO - 10.7150/jca.18012

M3 - Article

VL - 8

SP - 1223

EP - 1228

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 7

ER -